Top Markets
#1 0G 0G +23.70%
#2 Axelar Axelar +21.97%
#3 Cysic Cysic +21.57%
#4 Zora Zora +21.03%
#5 SAFEcoin SAFEcoin +19.60%
#6 Full Moon Full Moon +18.95%
#7 StonkBroker StonkBroker +16.85%
#8 AI XOVIA AI XOVIA +16.64%
#9 Merlin's Seal BTC Merlin's Seal BTC +16.61%
#10 ADO Protocol ADO Protocol +15.25%
Coin of the day
0G 0G
Settings
Language
ENGLISH
Currency
USD
Theme
Ocumension Therapeutics Ocumension Therapeutics

Ocumension Therapeutics

1477
Rank in Stocks #12973
Based in the People's Republic of China, Ocumension Therapeutics functions as a... Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.
Share Price
$0.66137861
Market Cap
$531.70M
Change (1 day)
-2.45%
Change (1 year)
-42.12%
Country
CN
Trade Ocumension Therapeutics (1477)

Category

Healthcare
P/E ratio for Ocumension Therapeutics (1477)
P/E ratio as of 2026 TTM: 0
According to Ocumension Therapeutics latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Ocumension Therapeutics from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.